Siân Bevan

Chief Science Officer

Arthritis Society

Dr. Siân Bevan is the Arthritis Society’s Chief Science Officer responsible for driving the scientific research, advocacy, public policy and programs and services agenda to maximize reach and impact. Siân completed her PhD in Medical Biophysics at the University of Toronto, after her undergraduate studies in Biochemistry at McGill University. 

Before joining the Arthritis Society, she held progressively senior roles at the Canadian Cancer Society where she was most recently the Vice-President of Research, providing scientific leadership and financial stewardship for the Cancer Society’s $40 million research program. In this role, Siân worked closely with the research community, promoted evidence-based public policy, program and information development, oversaw cancer surveillance efforts, identified and leveraged partnerships with medical, scientific and academic communities and worked closely with revenue development and communications teams. Before joining the Cancer Society she led the research programs team at the Ontario Genomics Institute working with the scientific community, federal and provincial research funders, academic institutions and hospitals to cultivate large scale genomics projects.

All Sessions by Siân Bevan

Printer Friendly See Full Agenda

Day 1: Oct 6, 2020

Day 2: Oct 7, 2020

Day 3: Oct 8, 2020

1:50 pm

1:50 pm

Panel Discussion

Improve Your Assessment of the Medical Cannabis Market with the Latest Pharmacoeconomics and Health Canada Policy Developments for Pharmacies

The use of medical cannabis has continued to increase in tandem with greater knowledge concerning its effectiveness in treating various disorders.  Decisions regarding whether your organization should include it in your pipeline or formulary need to be backed by an evidence-based approach.  Discover the latest developments in the use of medical cannabis to assist you to:

  • Better understand the opportunities this market represents and evaluate whether the benefits of entering it outweigh the risks of staying out
  • Assess the growing body of evidence that supports the use of medical cannabis especially among older patients
  • Gain insight into how Health Canada is moving forward with policies for cannabis products in pharmacies

Benefit your organization with an evidence-based approach to decisions on medical cannabis